For which complications would the nurse monitor in a patient receiving bevacizumab?
Background: Colorectal cancer (CRC) that has metastasized before being discovered, or reoccurs following surgery, remains a major treatment challenge. Trials have established the usefulness of antiangiogenic agents and new regimens in prolonging survival in patients with advanced disease. In the United States, the antiangiogenic agents approved for treating metastatic CRC often are combined with traditional chemotherapeutic agents and include bevacizumab (Avastin®), ziv-aflibercept (Zaltrap®), and regorafenib (Stivarga®). Show Objectives: This article reviews factors that guide the development of a nursing plan for monitoring and managing patients who are receiving antiangiogenic therapies. Methods: Regorafenib and ziv-aflibercept, two newer agents that nurses and other healthcare professionals may have had less experience with, were reviewed. Findings: The key to maximizing the potential benefit of these agents is understanding where these new therapies fit in the overall scheme of treatment options and how to help patients tolerate treatment. Not a current ONS member or journal subscriber? Receive a PDF to download and print. Medication Information Leaflet What is this medication for?Bevacizumab is used to treat some types of cancer (e.g. colorectal cancer, breast cancer, brain cancer, endometrial cancer, lung cancer and ovarian cancer). It is a monoclonal antibody which blocks VEGF (Vascular Endothelial Growth Factor), thus preventing the growth of blood vessels which supply oxygen and nutrients to the cancer cells. How should I take/use this medication?
What precautions should I take?Inform your healthcare professional if:
What are some common side-effects of this medication?Early Side Effects (within days after receiving Bevacizumab)
Delayed Side Effects (within days to weeks after receiving Bevacizumab)
If you experience any of these symptoms, you should see your healthcare professional immediately. You may refer to the following website if you need more information: https://www.macmillan.org.uk/ Disclaimers If you take more than the recommended dose, please seek medical advice immediately. The information provided on this page does not replace information from your healthcare professional. Please consult your healthcare professional for more information. This article is jointly developed by members of the National Medication Information workgroup. The workgroup consists of cluster partners (National Healthcare Group, National University Health System and SingHealth), community pharmacies (Guardian, Unity and Watsons) and Pharmaceutical Society of Singapore. The content does not reflect drug availability and supply information in pharmacies and healthcare institutions. You are advised to check with the respective institutions for such information. Last updated on May 2022 This article was last reviewed on Tuesday, October 4, 2022 What are the side effects of bevacizumab?Side Effects. Black, tarry stools.. body aches or pain.. burning, tingling, numbness, or pain in the hands, arms, feet, or legs.. chest pain, discomfort, or tightness.. cloudy urine.. cracks in the skin.. decreased urine output.. difficult or labored breathing.. Does Avastin cause high blood pressure?Avastin can increase your blood pressure. If you already have high blood pressure, Avastin could make this worse. Your doctor will check your blood pressure frequently while you receive Avastin. If your blood pressure gets too high, you may need medication to lower it.
When is Avastin contraindicated?Avastin is not indicated for patients with breast cancer that has progressed following anthracycline and taxane chemotherapy administered for metastatic disease. Avastin is indicated for the treatment of glioblastoma with progressive disease following prior therapy as a single agent.
Does Avastin cause diarrhea?These side effects included fatigue, nausea, nosebleeds, joint pain, diarrhea, and headache. For brain cancer treatment, Avastin's side effects were reported to be similar to those caused by other cancers in clinical trials.
|